David M. Chacko, M.D., serves as the Chief Financial Officer (CFO) and Chief Business Officer (CBO) at ERASCA INC, a pioneering biopharmaceutical company focused on developing novel therapies for cancer. Dr. Chacko brings a unique blend of medical and financial expertise to his role, having earned his M.D. from Harvard Medical School and an MBA from Stanford Graduate School of Business. Before joining ERASCA, he held significant positions in the biotech and pharmaceutical industries, including roles at Genentech, where he was instrumental in driving the company's strategic financial planning and business development initiatives. In his current position at ERASCA, Dr. Chacko is responsible for overseeing the company's financial operations, strategic planning, and business development efforts. His leadership has been pivotal in guiding ERASCA through various stages of growth, including securing funding and forging strategic partnerships that have propelled the company's research and development efforts. Under his stewardship, ERASCA has successfully advanced its pipeline of innovative cancer therapies, bringing hope to patients worldwide. Dr. Chacko's contributions extend beyond his corporate roles; he is also recognized for his thought leadership in the biotech sector. He frequently speaks at industry conferences and contributes to academic journals, sharing insights on the intersection of finance, medicine, and biotechnology. His dual expertise in medicine and business has made him a respected figure in the industry, and his work at ERASCA continues to drive the company toward its mission of transforming cancer treatment and improving patient outcomes.